Pfizer Inc. (NYSE:PFE) Shares Sold by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC cut its position in Pfizer Inc. (NYSE:PFE) by 14.6% in the fourth quarter, Holdings Channel reports. The firm owned 72,133 shares of the biopharmaceutical company’s stock after selling 12,317 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Pfizer were worth $1,914,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at about $26,000. Gladius Capital Management LP boosted its position in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Sierra Ocean LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at about $34,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management lifted its position in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 1.3 %

PFE opened at $26.40 on Thursday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $149.63 billion, a P/E ratio of 18.73, a P/E/G ratio of 0.64 and a beta of 0.64. The business has a 50 day simple moving average of $26.34 and a 200-day simple moving average of $27.36. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the business posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.51%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.